Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P0CW18
UPID:
PRS56_HUMAN
Alternative names:
-
Alternative UPACC:
P0CW18
Background:
Serine protease 56 plays a pivotal role in eye development, acting as a crucial enzyme in the process. Its specific function as a serine protease underscores its importance in the biological mechanisms that shape the ocular system.
Therapeutic significance:
Linked to Microphthalmia, isolated, 6, a condition characterized by small, malformed eyes and a range of visual impairments, Serine protease 56's involvement in this disease highlights its potential as a target for therapeutic intervention. Understanding the role of Serine protease 56 could open doors to potential therapeutic strategies.